These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

314 related articles for article (PubMed ID: 27197535)

  • 1. Part I: Checkpoint inhibitors in cancer therapy.
    Daud AI
    Immunotherapy; 2016 Jun; 8(6):675-6. PubMed ID: 27197535
    [No Abstract]   [Full Text] [Related]  

  • 2. Part II: Checkpoint inhibitors in cancer therapy.
    Daud AI
    Immunotherapy; 2016 Jun; 8(7):761-2. PubMed ID: 27349974
    [No Abstract]   [Full Text] [Related]  

  • 3. Targeting T Cell Co-receptors for Cancer Therapy.
    Callahan MK; Postow MA; Wolchok JD
    Immunity; 2016 May; 44(5):1069-78. PubMed ID: 27192570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Which checkpoint inhibitor? An embarrassment of riches for bladder cancer.
    Gill DM; Sonpavde G; Pal SK; Agarwal N
    Immunotherapy; 2017 May; 9(6):463-466. PubMed ID: 28472906
    [No Abstract]   [Full Text] [Related]  

  • 5. The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.
    van Dam LS; de Zwart VM; Meyer-Wentrup FA
    Pediatr Blood Cancer; 2015 Feb; 62(2):190-197. PubMed ID: 25327979
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Introduction: Cancer Immunology Special Issue-Immunotherapy.
    Kawakami Y
    Int Immunol; 2016 Jul; 28(7):317. PubMed ID: 27313100
    [No Abstract]   [Full Text] [Related]  

  • 7. Weighing up the pros and cons of immune checkpoint inhibitors in the treatment of melanoma.
    Spain L; Larkin J
    Immunotherapy; 2016 Jun; 8(6):677-9. PubMed ID: 27197536
    [No Abstract]   [Full Text] [Related]  

  • 8. Neoantigen heterogeneity: a key driver of immune response and sensitivity to immune checkpoint blockade?
    Furness AJ; Quezada SA; Peggs KS
    Immunotherapy; 2016 Jun; 8(7):763-6. PubMed ID: 27349975
    [No Abstract]   [Full Text] [Related]  

  • 9. STING signaling: a key to therapeutic tumor immunity.
    Foote JB; Emens LA
    Immunotherapy; 2018 Jul; 10(9):729-731. PubMed ID: 30008260
    [No Abstract]   [Full Text] [Related]  

  • 10. Coinhibitory Pathways in Immunotherapy for Cancer.
    Baumeister SH; Freeman GJ; Dranoff G; Sharpe AH
    Annu Rev Immunol; 2016 May; 34():539-73. PubMed ID: 26927206
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune-Checkpoint Inhibitors in the Era of Precision Medicine: What Radiologists Should Know.
    Braschi-Amirfarzan M; Tirumani SH; Hodi FS; Nishino M
    Korean J Radiol; 2017; 18(1):42-53. PubMed ID: 28096717
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Emerging Concepts for Immune Checkpoint Blockade-Based Combination Therapies.
    Zappasodi R; Merghoub T; Wolchok JD
    Cancer Cell; 2018 Apr; 33(4):581-598. PubMed ID: 29634946
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PD-1/PD-L1 in disease.
    Kuol N; Stojanovska L; Nurgali K; Apostolopoulos V
    Immunotherapy; 2018 Feb; 10(2):149-160. PubMed ID: 29260623
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immune checkpoint inhibition in ovarian cancer.
    Hamanishi J; Mandai M; Konishi I
    Int Immunol; 2016 Jul; 28(7):339-48. PubMed ID: 27055470
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Do immune-related adverse events correlate with response to immune checkpoint inhibitors?
    Saleh K; Khalife-Saleh N; Kourie HR
    Immunotherapy; 2019 Mar; 11(4):257-259. PubMed ID: 30678551
    [No Abstract]   [Full Text] [Related]  

  • 16. Anti-CTLA-4 therapy for malignant mesothelioma.
    Guazzelli A; Bakker E; Krstic-Demonacos M; Lisanti MP; Sotgia F; Mutti L
    Immunotherapy; 2017 Mar; 9(3):273-280. PubMed ID: 28231719
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Could PD-1/PDL1 immune checkpoints be linked to HLA signature?
    Correale P; Saladino RE; Nardone V; Giannicola R; Agostino R; Pirtoli L; Caraglia M; Botta C; Tagliaferri P
    Immunotherapy; 2019 Dec; 11(18):1523-1526. PubMed ID: 31865873
    [No Abstract]   [Full Text] [Related]  

  • 18. Hiding in Plain Sight: Soluble Immunomodulatory Receptors.
    Dahal LN; Schwarz H; Ward FJ
    Trends Immunol; 2018 Oct; 39(10):771-774. PubMed ID: 30195467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The present status and future prospects of peptide-based cancer vaccines.
    Hirayama M; Nishimura Y
    Int Immunol; 2016 Jul; 28(7):319-28. PubMed ID: 27235694
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The CD47-SIRPĪ± signaling axis as an innate immune checkpoint in cancer.
    Matlung HL; Szilagyi K; Barclay NA; van den Berg TK
    Immunol Rev; 2017 Mar; 276(1):145-164. PubMed ID: 28258703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.